8-K: uniQure Faces FDA Hurdle for AMT-130, Reports 2025 Results

uniQure announced its 2025 financial results and pipeline updates, including a significant regulatory setback for its Huntington's disease gene therapy, AMT-130, with the FDA requiring a Phase III study.

Summary

• Reported financial results for the fourth quarter and full year ended December 31, 2025.
• The FDA stated that Phase I/II data for AMT-130, an investigational gene therapy for Huntington's disease, are insufficient to support a marketing application and strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study.
• The company plans to request a Type B meeting with the FDA in the second quarter of 2026 to further discuss potential Phase III study design approaches for AMT-130.
• Completed enrollment of the first cohort in the Phase I/IIa study of AMT-260 in refractory mesial temporal lobe epilepsy, with additional clinical data expected in the first half of 2026.
• Presented updated Phase I/II data from AMT-191 in Fabry disease showing durable, dose-dependent increases in α-Gal A enzyme activity, but paused additional dosing in midand high-dose cohorts due to dose-limiting liver enzyme elevations.
• Enrollment for AMT-162 for SOD1 amyotrophic lateral sclerosis (ALS) remains on voluntary pause following an Independent Data Monitoring Committee recommendation after review of preliminary safety and efficacy data, which included one serious adverse event of dose-limiting toxicity.
• Cash, cash equivalents, and current investment securities were approximately $622.5 million as of December 31, 2025, expected to fund operations into the second half of 2029.
• Net loss for the year ending December 31, 2025, was $199.0 million, an improvement from a $239.6 million net loss in 2024.
• Revenue for 2025 was $16.1 million, a decrease from $27.1 million in 2024.
• Research and development expenses decreased slightly to $140.7 million in 2025 from $143.8 million in 2024.
• Selling, general and administrative expenses increased to $65.5 million in 2025 from $52.7 million in 2024, partly due to preparation for AMT-130 commercialization.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a negative development due to the significant regulatory setback for AMT-130, the company's lead program, which will delay its path to market and increase development costs, despite a strong cash position and some positive early-stage data for other programs.

Positives

• Strong cash position of $622.5 million as of December 31, 2025, which is expected to fund operations into the second half of 2029.
• Net loss improved to $199.0 million in 2025 from $239.6 million in 2024.
• AMT-130 showed a statistically significant 75% slowing in disease progression measured by cUHDRS (p=0.003) and a 60% slowing in Total Functional Capacity (p=0.033) compared to external controls in Phase I/II studies.
• AMT-130 was generally well-tolerated across both doses, with a manageable safety profile and no new drug-related serious adverse events observed since December 2022.
• AMT-260 demonstrated a 92% reduction in seizure frequency in the first treated patient through the first five months of follow-up, with no serious safety events.
• AMT-191 showed durable, dose-dependent elevations in α-Gal A activity across three dose levels, with six of 11 dosed patients withdrawn from enzyme replacement therapy (ERT).
• Successfully raised aggregate net proceeds of $404.2 million through follow-on public offerings in 2025.
• Refinanced existing $50 million debt to extend the term to October 2030 and reduce its cost of capital.

Negatives

• The FDA stated that Phase I/II data for AMT-130 are insufficient for a marketing application and strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study, indicating a significant delay to potential market approval.
• Revenue decreased by $11.0 million in 2025 compared to 2024, primarily driven by decreases in collaboration and contract manufacturing revenues.
• Additional dosing in the midand high-dose cohorts for AMT-191 has been paused pending further evaluation of asymptomatic Grade 3 liver enzyme elevations reported in two patients, which were confirmed as dose-limiting toxicities.
• Enrollment for AMT-162 remains on voluntary pause following an Independent Data Monitoring Committee recommendation due to a serious adverse event of dose-limiting toxicity related to the treatment.
• Selling, general and administrative expenses increased by $12.8 million, partly due to preparation for the planned commercialization of AMT-130, which now faces a significant regulatory hurdle.

Risks

• Clinical results may be unable to demonstrate data sufficient to support further clinical development or regulatory approval in any country where approval is pursued.
• More patient data may become available that results in a different interpretation than the one derived from preliminary, interim, or topline data.
• Interactions with regulatory authorities, including the FDA, may affect the initiation, timing, and progress of clinical trials and pathways and timing for regulatory approval.
• Whether the measurements being evaluated are viewed as robust and sensitive measurements of disease progression suitable for regulatory approval.
• The company's ability to conduct and fund a Phase III or confirmatory study for AMT-130.
• The company's ability to continue to build and maintain the infrastructure and personnel needed to achieve its goals.
• The company's effectiveness in managing current and future clinical trials and regulatory processes.
• The continued development and acceptance of gene therapies.
• The company's ability to demonstrate the therapeutic benefits of its gene therapy candidates in clinical trials.
• The company's ability to obtain, maintain, and protect intellectual property.
• The company's ability to fund its operations and to raise additional capital as needed and on acceptable terms.

Future Outlook

The company expects its cash, cash equivalents, and investment securities to be sufficient to fund operations into the second half of 2029. It plans to continue engaging with the FDA regarding Phase III development considerations for AMT-130 and request a Type B meeting in the second quarter of 2026. Additional clinical data from the AMT-260 program are expected in the first half of 2026. The company remains financially disciplined and well-positioned to continue advancing its programs strategically and responsibly.

Management Comments

• "While we have not reached alignment with the FDA on an approval pathway, we remain confident in the strength and durability reflected in our dataset." Matt Kapusta, chief executive officer.
• "We are committed to engaging with the FDA to define a clear and efficient path to bring this potentially transformative therapy to Huntington's disease patients in urgent need for treatments." Matt Kapusta, chief executive officer.
• "Beyond Huntington's disease, we have also made meaningful progress across our broader clinical portfolio and look forward to additional data readouts later this year." Matt Kapusta, chief executive officer.
• "Entering 2026 with a strong balance sheet, we remain financially disciplined and well-positioned to continue advancing our programs strategically and responsibly." Matt Kapusta, chief executive officer.
• "While we did not reach alignment on a submission pathway based on the Phase I/II data, we believe the totality and durability of our data warrant continued substantive dialogue regarding how the FDA's stated commitment to regulatory flexibility may be appropriately applied in this setting." Matt Kapusta, chief executive officer.
• "We are deeply grateful for the resilience and support of the Huntington's disease community and remain committed to standing with patients and their families as we advance this potentially transformative therapy for a community in need." Matt Kapusta, chief executive officer.

Industry Context

StockSavvy.ai notes that the gene therapy sector is highly innovative but also faces significant regulatory hurdles, particularly for novel treatments targeting severe rare diseases like Huntington's. The FDA's recommendation for a prospective, randomized, double-blind, sham surgery-controlled Phase III study for AMT-130 underscores the agency's rigorous evidence requirements, even for therapies showing promising early-stage data in areas of high unmet medical need. This decision could set a precedent for other gene therapy developers relying on external controls for accelerated approval pathways, highlighting the ongoing tension between rapid patient access and robust clinical evidence in genomic medicine.

Comparison to Industry Standards

• The FDA's requirement for a prospective, randomized, double-blind, sham surgery-controlled study for AMT-130 aligns with the highest evidentiary standards for drug approval, similar to what is typically expected for novel therapies in large indications. This contrasts with some accelerated approval pathways granted for rare diseases, where smaller, single-arm studies with external controls might be considered sufficient if the unmet need is extremely high and the data compelling.
• For example, Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy, Elevidys, received accelerated approval based on a single-arm study, but faced significant debate and post-marketing requirements. uniQure's situation suggests the FDA is taking a more conservative stance for AMT-130, potentially due to the complexity of Huntington's disease and the specific data package presented.
• The dose-limiting toxicities observed in AMT-191 (Fabry disease) and AMT-162 (ALS) are not uncommon in early-stage gene therapy development, where optimizing dose and delivery is critical. Companies like Voyager Therapeutics and Audentes Therapeutics have also faced clinical holds or program adjustments due to safety concerns in their gene therapy pipelines, indicating that such challenges are part of the standard development process in this high-risk, high-reward field.

Stakeholder Impact

• Shareholders face potential negative impact due to the significant delay in AMT-130's path to market, increased R&D costs for a Phase III study, and uncertainty regarding regulatory approval. The strong cash position provides a buffer, but the news is likely to be price-sensitive.
• Patients with Huntington's disease will experience a delay in access to a potentially transformative therapy, requiring them to wait longer for a new treatment option.
• Employees will need to focus on the new R&D requirements for AMT-130, potentially facing pressure to deliver on the extended development timeline.
• Creditors may be impacted as the $100 million additional term loan tranche is contingent on an AMT-130 regulatory milestone, which is now delayed, affecting potential future drawdowns.

Next Steps

• Request a Type B meeting with the FDA in the second quarter of 2026 to further discuss potential Phase III study design approaches for AMT-130.
• Provide updated data from the AMT-260 Phase I/IIa study in the first half of 2026.
• Continue to collect and evaluate data from the five patients treated in the AMT-162 Phase I/II EPISOD1 study.
• Attend upcoming investor events: TD Cowen 46th Annual Health Care Conference (March 2nd), Leerink Global Partners Global Healthcare Conference (March 11th), Barclays 28th Annual Global Healthcare Conference (March 12th), and Kempen Life Science Conference (April 15th).

Key Dates

Recommendation

The FDA's rejection of the current data package for AMT-130 and the strong recommendation for a costly and time-consuming Phase III study represent a major setback for uniQure's lead program. This significantly delays potential market entry and increases financial risk, despite a healthy cash balance. While other pipeline assets show promise, the immediate future for the most advanced program is clouded by regulatory uncertainty and extended development timelines, making the stock a "sell" for seasoned investors seeking near-term catalysts or clearer regulatory pathways.

Keywords

uniQure, QURE, gene therapy, Huntington's disease, AMT-130, FDA, regulatory update, clinical trials, Phase III, epilepsy, AMT-260, Fabry disease, AMT-191, ALS, AMT-162, financial results, cash position, biotech, pharmaceutical